U.S. Markets closed

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8300-0.0400 (-2.14%)
At close: 4:00PM EDT

1.8700 +0.04 (2.19%)
After hours: 5:07PM EDT

TRACON Pharmaceuticals, Inc.

4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122
United States
858-550-0780
http://www.traconpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Dr. Charles P. TheuerCEO, Pres & Director826.76kN/A1964
Mr. Scott B. Brown CPA, M.S.Chief Accounting Officer & Head of Fin.445.04kN/A1981
Mr. Mark C. Wiggins M.B.A.Chief Bus. Officer501.84kN/A1956
Ms. Bonne AdamsExec. VP of Clinical OperationsN/AN/A1977
Mr. Shahe GarabedianSr. VP & Head of Quality AssuranceN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Corporate Governance

TRACON Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.